133 related articles for article (PubMed ID: 37848029)
1. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV.
Sun C; Kang YF; Fang XY; Liu YN; Bu GL; Wang AJ; Li Y; Zhu QY; Zhang H; Xie C; Kong XW; Peng YJ; Lin WJ; Zhou L; Chen XC; Lu ZZ; Xu HQ; Hong DC; Zhang X; Zhong L; Feng GK; Zeng YX; Xu M; Zhong Q; Liu Z; Zeng MS
Cell Host Microbe; 2023 Nov; 31(11):1882-1897.e10. PubMed ID: 37848029
[TBL] [Abstract][Full Text] [Related]
2. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
[TBL] [Abstract][Full Text] [Related]
3. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
4. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
5. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection.
Kang YF; Zhang X; Yu XH; Zheng Q; Liu Z; Li JP; Sun C; Kong XW; Zhu QY; Chen HW; Huang Y; Xu M; Zhong Q; Zeng YX; Zeng MS
Nano Lett; 2021 Mar; 21(6):2476-2486. PubMed ID: 33683126
[TBL] [Abstract][Full Text] [Related]
7. A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection.
Zhong L; Zhang W; Liu H; Zhang X; Yang Z; Wen Z; Chen L; Chen H; Luo Y; Chen Y; Feng Q; Zeng MS; Zhao Q; Liu L; Krummenacher C; Zeng YX; Chen Y; Xu M; Zhang X
Nat Commun; 2024 Jun; 15(1):5310. PubMed ID: 38906867
[TBL] [Abstract][Full Text] [Related]
8. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
9. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion.
Zhang X; Hong J; Zhong L; Wu Q; Zhang S; Zhu Q; Chen H; Wei D; Li R; Zhang W; Zhang X; Wang G; Zhou X; Chen J; Kang Y; Zha Z; Duan X; Huang Y; Sun C; Kong X; Zhou Y; Chen Y; Ye X; Feng Q; Li S; Xiang T; Gao S; Zeng MS; Zheng Q; Chen Y; Zeng YX; Xia N; Xu M
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2202371119. PubMed ID: 35917353
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.
Malhi H; Homad LJ; Wan YH; Poudel B; Fiala B; Borst AJ; Wang JY; Walkey C; Price J; Wall A; Singh S; Moodie Z; Carter L; Handa S; Correnti CE; Stoddard BL; Veesler D; Pancera M; Olson J; King NP; McGuire AT
Cell Rep Med; 2022 Jun; 3(6):100658. PubMed ID: 35705092
[TBL] [Abstract][Full Text] [Related]
11. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge
Hong J; Zhong L; Zheng Q; Wu Q; Zha Z; Wei D; Chen H; Zhang W; Zhang S; Huang Y; Chen K; Chen J; Li S; Zeng MS; Zeng YX; Xia N; Zhang X; Xu M; Chen Y
J Virol; 2022 Apr; 96(8):e0007522. PubMed ID: 35348362
[TBL] [Abstract][Full Text] [Related]
12. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
[TBL] [Abstract][Full Text] [Related]
13. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
14. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
15. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
16. Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge.
Cui X; Cao Z; Ishikawa Y; Cui S; Imadome KI; Snapper CM
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33808755
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.
Chen WH; Kim J; Bu W; Board NL; Tsybovsky Y; Wang Y; Hostal A; Andrews SF; Gillespie RA; Choe M; Stephens T; Yang ES; Pegu A; Peterson CE; Fisher BE; Mascola JR; Pittaluga S; McDermott AB; Kanekiyo M; Joyce MG; Cohen JI
Immunity; 2022 Nov; 55(11):2135-2148.e6. PubMed ID: 36306784
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.
Edwards KR; Schmidt K; Homad LJ; Kher GM; Xu G; Rodrigues KA; Ben-Akiva E; Abbott J; Prlic M; Newell EW; De Rosa SC; Irvine DJ; Pancera M; McGuire AT
Cell Rep Med; 2024 Jun; 5(6):101587. PubMed ID: 38781964
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
Herrman M; Mühe J; Quink C; Wang F
J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
[TBL] [Abstract][Full Text] [Related]
20. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]